ASTRAZEN - IntraDay Trade Analysis with Live Signals
Back to ListHere’s the intraday trading report for ASTRAZEN based on the given parameters
IntraDay Trade Rating: 3.4
| Stock Code | ASTRAZEN | Market Cap | 21,302 Cr. | Current Price | 8,529 ₹ | High / Low | 9,850 ₹ |
| Stock P/E | 111 | Book Value | 349 ₹ | Dividend Yield | 0.38 % | ROCE | 29.3 % |
| ROE | 23.3 % | Face Value | 2.00 ₹ | DMA 50 | 8,484 ₹ | DMA 200 | 8,551 ₹ |
| Chg in FII Hold | 0.07 % | Chg in DII Hold | 0.24 % | PAT Qtr | 45.7 Cr. | PAT Prev Qtr | 31.6 Cr. |
| RSI | 51.8 | MACD | -16.5 | Volume | 2,288 | Avg Vol 1Wk | 3,968 |
| Low price | 7,552 ₹ | High price | 9,850 ₹ | PEG Ratio | 7.48 | Debt to equity | 0.13 |
| 52w Index | 42.5 % | Qtr Profit Var | -26.6 % | EPS | 75.0 ₹ | Industry PE | 32.1 |
📊 Analysis: ASTRAZEN is trading just above its 50 DMA (₹8,484) and near the 200 DMA (₹8,551), showing neutral positioning. RSI at 51.8 indicates weak momentum, while MACD at -16.5 reflects bearish divergence. Intraday volume (2,288) is below the weekly average (3,968), suggesting limited upside potential.
💹 Optimal Buy Price: ₹8,480 – ₹8,520 (near DMA support)
🎯 Profit Exit Levels: ₹8,600 – ₹8,650 (short-term resistance zone)
🛑 Stop-Loss: ₹8,440 (below 50 DMA support)
⏳ Exit Strategy if Holding: Exit intraday if RSI drops below 50 with rising sell volume or if price falls under ₹8,440 with strong bearish candles. On the upside, partial profit booking is advised near ₹8,600–₹8,650 if momentum weakens.
✅ Positive
- Strong ROE (23.3%) and ROCE (29.3%) indicate efficient capital use.
- Debt-to-equity ratio at 0.13 ensures financial stability.
- PAT improved to ₹45.7 Cr. from ₹31.6 Cr. in the previous quarter.
⚠️ Limitation
- High P/E (111) compared to industry average (32.1).
- PEG ratio at 7.48 suggests overvaluation relative to growth.
- Quarterly profit variation (-26.6%) raises earnings consistency concerns.
- Intraday volume below average, limiting momentum.
📉 Company Negative News
- EPS stagnated at ₹75.0 despite high valuation multiples.
- Profitability volatility with recent quarter drop (-26.6%).
📈 Company Positive News
- PAT recovery from ₹31.6 Cr. to ₹45.7 Cr. shows resilience.
- FII holding increased (+0.07%) and DII holding also rose (+0.24%).
🏭 Industry
- Pharma sector trading at industry PE of 32.1, much lower than ASTRAZEN’s valuation.
- Sector rotation favors defensive pharma stocks, but valuations remain stretched.
🔎 Conclusion
ASTRAZEN is a moderately suitable intraday candidate today. Entry near ₹8,480–₹8,520 offers limited upside toward ₹8,600–₹8,650. Weak volume and bearish MACD suggest caution, requiring disciplined stop-loss management.
Would you like me to extend this into a peer benchmarking overlay comparing ASTRAZEN with Sun Pharma, Dr. Reddy’s, and Cipla for clearer sector positioning?